← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Focal Medical, Inc.
Cary, NC
$6,482,594
Total funding
2
Grants
Funding over time
peak $2M · FY2017–24$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,482,594 · 2
By mechanism
R44$6,184,629 · 1
N43$297,965 · 1
Investigators at Focal Medical, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Implantable iontophoresis chemotherapy delivery device for direct infusion ofgemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial$2,000,000
R44 · FY2022 · CA
Implantable iontophoresis chemotherapy delivery device for direct infusion ofgemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial$2,000,000
R44 · FY2021 · CA
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial$1,111,364
R44 · FY2018 · CA
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial$771,376
R44 · FY2019 · CA
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial$299,805
R44 · FY2017 · CA
2024 SBIR CONCEPT CLEARANCE AWARD$297,965
N43 · FY2024 · CA
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial$2,084
R44 · FY2019 · CA